Preclinical News and Research

RSS

New drug application for regulatory approval of exenatide for the treatment of type 2 diabetes

Amylin Pharmaceuticals, Inc., and Eli Lilly and Company today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for regulatory approval of exenatide.

1 Jul 2004

Alcon updates filing status of RETAANE® new drug application

Alcon, Inc. has announced that it has filed the second portion of its “rolling” New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for RETAANE® 15mg (anecortave acetate for depot suspension)

30 Jun 2004

Duloxetine reduces stress urinary incontinence and improves quality of life for women

Data presented today at the 3rd International Consultation on Incontinence, provide evidence for the efficacy of duloxetine, an investigational agent for the treatment of women with stress urinary incontinence (SUI).

29 Jun 2004

Exelixis files new drug application for a proprietary novel anticancer compound

Exelixis, Inc. has submitted an investigational new drug application (IND) to the U.S. Food and Drug Administration (FDA) for XL999, a proprietary novel anticancer compound.

29 Jun 2004

Gene chip technology can detect one of the commonest cystic fibrosis (CF) genetic mutations with 100% accuracy

A single genetic test that is capable of detecting all mutations involved in the development of cystic fibrosis could be just a few years away, the 20th annual conference of the European Society of Human Reproduction and Embryology heard today (Monday 28 June).

28 Jun 2004

Paclitaxel analog kills more cancer cells than natural product

Paclitaxel, a natural compound from yew trees, is the world's best-selling anticancer drug. Several analogs are in clinical trial, with others in preclinical development. One problem that paclitaxel and all its analogs share, however, is that they are all highly complex compounds, and cannot be prepared synthetically in a commercially viable way.

21 Jun 2004

Early patient response to Forteo in postmenopausal women with osteoporosis

Changes in markers of bone remodeling after one month of treatment with FORTEO® (teriparatide [rDNA origin] injection) may provide important early evidence of treatment response, according to new data presented today at the 86th Annual Meeting of The Endocrine Society (ENDO).

17 Jun 2004

Ultrasound technology to treat cancer

Ultrasound scans might be most familiar for getting a peek at a developing fetus, but the technology could also be used to treat cancer. A partnership between UC Davis, Siemens Medical Systems and ImaRx Inc., funded by a National Cancer Institute grant, will study ways to deliver drugs to tumors using focused ultrasound.

17 Jun 2004

SARS siRNA studied further to help many respiratory diseases including lung cancer

Intradigm Corporation, has announced achievement of prophylactic and therapeutic effects of siRNA (small interfering RNA) inhibitors of SARS-CoV in non-human primate cells. The results are published in the June 2004 issue of Antiviral Therapy (International Medical Press).

15 Jun 2004

New whole body positron emission tomography (PET) imaging allows scientists to watch as immune system respond to tumors or infection

Compared to the snapshot views of the immune system from tumor biopsies or blood assays, this whole body imaging allows scientists to track how the immune response changes, and the tumor or infection responds, throughout the different phases of immune response and over long periods of time.

15 Jun 2004

$2.5 billion will be invested in the search for type 1 diabetes cure for over next 5 years

The Juvenile Diabetes Research Foundation (JDRF), the world's leading charitable funder of research leading to a cure of type 1 diabetes and its complications, held the Global Diabetes Research Forum today as part of its annual meeting in Washington, DC.

14 Jun 2004

Outsourcing the way to control spiraling R&D budgets in drug industry

Companies developing new drugs for the global market must deal with the rising costs of the R&D process – and outsourcing may well be the best route. That's the verdict of Dr Faiz Kermani, a specialist in outsourcing and research development for the pharmaceutical industry.

14 Jun 2004

Better understanding of Tamoxifen and how breast cancer patients develop resistance

A new study by researchers at Georgetown’s Lombardi Comprehensive Cancer Center may have implications for the thousands of breast cancer patients who develop resistance to antiestrogen drugs such as Tamoxifen®. The work is published in the June 1 issue of Cancer Research.

11 Jun 2004

Foundation for poor heart health laid early in life

Heart disease - long viewed as a scourge of adulthood - is a growing threat to children because of soaring rates of obesity and related problems, such as diabetes.

9 Jun 2004

Velcade major improvement over standard therapy for relapsed multiple myeloma

Early results from a major, international Phase III clinical trial decisively show that recurrent multiple myeloma is more effectively treated with the drug bortezomib (trade name: Velcade TM) than with dexamethasone, a drug that for decades has been the standard therapy for relapsed disease, researchers at Dana-Farber Cancer Institute report.

6 Jun 2004

Avastin study shows significant improvement in patients with metastatic colorectal cancer

Genentech, Inc. and Roche have announced that the New England Journal of Medicine published the first Phase III study of an anti-angiogenesis cancer therapy, showing that the addition of Avastin™ (bevacizumab) to the IFL chemotherapy regimen (5-FU/Leucovorin/ CPT-11) significantly extended survival in patients with first-line (previously untreated) metastatic colorectal cancer.

2 Jun 2004

BioSante publishes oral insulin study

BioSante Pharmaceuticals, Inc. has announced the publication of positive results of a preclinical study of its proprietary calcium phosphate nanoparticle (CAP) delivery system for the oral delivery of insulin in the June 11 issue of the peer-reviewed International Journal of Pharmaceutics.

2 Jun 2004

Women who regularly take aspirin at lower risk of breast cancer

Women who regularly take aspirin seem to be at lower risk of the most common type of breast cancer than those who do not take aspirin, report researchers from Columbia University's Mailman School of Public Health and College of Physicians & Surgeons, Weill Cornell Medical College , and New York-Presbyterian Hospital.

31 May 2004

Research tests the efficacy of a smallpox vaccine candidate known as LC16m8

When used as an aerosolized weapon, smallpox could be controlled by a new vaccine under study at Saint Louis University School of Medicine, according to new data.

27 May 2004

New company is developing advanced therapeutics for stroke victims

Arizona Engineered Therapeutics Inc., a new company based on the research of three Arizona State University professors, is moving its first drug candidate closer to clinical trials.

26 May 2004